Daily, national news headlines call attention to the lack of adequate testing for COVID-19. News reporters question why clinical labs are unable to meet the demand for SARS-CoV-2 tests. One major reason is the lack of adequate supplies labs need to collect specimens, transport them, and perform COVID-19 tests in large numbers. This is one finding of a study conducted by the Association for Molecular Pathology (AMP). In a press release issued last Thursday, it reported that supply chain issues are one major reason why clinical labs are unable to perform large numbers of COVID-19 tests.
MORE ON: COVID-19 Tests and Supply Chain
AMP said its survey generated 118 complete responses, of which 95 labs were AMP members and 23 labs were non-members. It wrote, “the types of supply chain interruptions that laboratories experienced were vast and include testing platforms, testing kits, reagents, swabs, viral transport media (VTM), laboratory consumables, and PPE, with swabs being the biggest limitation across laboratories.” For labs which complain that when shipping supplies vendors favor some labs over others, the AMP survey offers evidence that this may be true. In response to questions about the restrictions and allocation of testing kitsand reagents, 70% of hospital and health system labs and 64% of academic medical center labs said they were unable to get adequate quantities due to either government restrictions or how vendors were allocating kits. By contrast, only 13% of commercial reference laboratories said they could not get adequate supplies.
COVID-19 BRIEFINGS WEBSITE FOR LABS
In recent weeks, The Dark Report initiated a free dailyservice that provides realtime news, information, and alerts to help clinical labs and pathology groups respond to the COVID-19 pandemic.The COVID-19 STAT Intelligence Briefings website is: https://covid19briefings.com. COVID-19 Live! calls lasting 30 minutes take place every Tuesday and Thursday at 1:00 PM EDT. All lab professionals are invited to participate.
• Progenity, Inc., of Austin, Texas, announced that Damon Silvestry is now its new Chief Operating Officer. He previously held executive positions at Natera, Miraca Life Sciences, Recy-Kleen, and Dell.
• Tony Serafini-Lamanna was promoted to Executive Vice President, Diagnostics, at Meridian Bioscience Inc., of Cincinnati, Ohio. Prior to Meridian, he was with Siemens Healthcare Diagnostics.
DARK DAILY UPDATE
Have you caught the latest e-briefings from DARK Daily? If so, then you’d know …
…when and why patients stopped showing up in doctors ’offices, ERs, and other healthcare settings because of the COVID-19 outbreak, causing a huge drop in the daily volume of routine testing referred to labs and pathology groups.
You can get the free DARK Daily e-briefings by signing up www.darkdaily.com.
That’s all the insider intelligence for this report. Look for the next briefing on Monday, June 22, 2020.